Background: The efficacy and safety of intracerebral gene therapy for brain disorders like Parkinson's disease depends on the appropriate distribution of gene expression. Objectives: To assess whether the distribution of gene expression is affected by vector titer and protein type. Methods: Four adult macaque monkeys seronegative for adeno-associated virus 5 (AAV5) received a 30-µl inoculation of a high- or a low-titer suspension of AAV5 encoding glial cell line-derived neurotrophic factor (GDNF) or green fluorescent protein (GFP) in the right and left ventral postcommissural putamen. The inoculations were conducted using convection-enhanced delivery and intraoperative MRI (IMRI). Results: IMRI confirmed targeting and infusion cloud irradiation from the catheter tip into the surrounding area. A postmortem analysis 6 weeks after surgery revealed GFP and GDNF expression ipsilateral to the injection site that had a titer-dependent distribution. GFP and GDNF expression was also observed in fibers in the substantia nigra (SN) pars reticulata (pr), demonstrating anterograde transport. Few GFP-positive neurons were present in the SN pars compacta (pc), possibly by direct retrograde transport of the vector. GDNF was present in many neurons of the SNpc and SNpr. Conclusions: After controlling for target and infusate volume, the intracerebral distribution of the gene product was affected by the vector titer and product biology.

1.
Sampson JH, Raghavan R, Brady M, Friedman AH, Bigner D: Convection-enhanced delivery. J Neurosurg 2011;115:463-464, discussion 465-466.
2.
Kimmelman J, Duckworth K, Ramsay T, Voss T, Ravina B, et al: Risk of surgical delivery to deep nuclei: a meta-analysis. Mov Disord 2011;26:1415-1421.
3.
Emborg ME, Joers V, Fisher R, Brunner K, Carter V, et al: Intraoperative intracerebral MRI-guided navigation for accurate targeting in nonhuman primates. Cell Transplant 2010;19:1587-1597.
4.
Brady ML, Raghavan R, Alexander A, Kubota K, Sillay K, et al: Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus. Stereotact Funct Neurosurg 2013;91:69-78.
5.
San Sebastian W, Richardson RM, Kells AP, Lamarre C, Bringas J, et al: Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther 2012;23:210-217.
6.
Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, et al: Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004;10:302-317.
7.
Peden CS, Burger C, Muzyczka N, Mandel RJ: Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004;78:6344-6359.
8.
Su X, Kells AP, Salegio EA, Richardson RM, Hadaczek P, et al: Real-time MR imaging with gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther 2010;18:1490-1495.
9.
Morrison PF, Lonser RR, Oldfield EH: Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg 2007;107:74-83.
10.
Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, et al: Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-1172.
11.
Urabe M, Nakakura T, Xin KQ, Obara Y, Mizukami H, et al: Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells. J Virol 2006;80:1874-1885.
12.
Unzu C, Hervas-Stubbs S, Sampedro A, Mauleon I, Mancheno U, et al: Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med 2012;10:122.
13.
Emborg ME, Moirano J, Raschke J, Bondarenko V, Zufferey R, et al: Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 2009;36:303-311.
14.
Paxinos G: The Rhesus Monkey Brain in Stereotaxic Coordinates. Waltham, Academic Press, 2000.
15.
Swanson CR, Emborg ME: Expression of peroxisome proliferator-activated receptor-γ in the substantia nigra of hemiparkinsonian nonhuman primates. Neurol Res 2013, Epub ahead of print.
16.
Ohshima-Hosoyama S, Simmons HA, Goecks N, Joers V, Swanson CR, et al: A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys. PLoS One 2012;7:e39036.
17.
Hullinger R, Ugalde J, Puron-Sierra L, Osting S, Burger C: The MRI contrast agent gadoteridol enhances distribution of rAAV1 in the rat hippocampus. Gene Ther 2013;20:1171-1177.
18.
Gasmi M, Herzog CD, Brandon EP, Cunningham JJ, Ramirez GA, et al: Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 2007;15:62-68.
19.
Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, et al: Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods 2010;194:144-153.
20.
Burger C, Nguyen FN, Deng J, Mandel RJ: Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. Mol Ther 2005;11:327-331.
21.
Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, et al: Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 2007;27:501-509.
22.
LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, et al: AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011;10:309-319.
23.
Wolak DJ, Thorne RG: Diffusion of macromolecules in the brain: implications for drug delivery. Mol Pharm 2013;10:1492-1504.
24.
Hamilton JF, Morrison PF, Chen MY, Harvey-White J, Pernaute RS, et al: Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp Neurol 2001;168:155-161.
25.
Opie SR, Warrington KH Jr, Agbandje-McKenna M, Zolotukhin S, Muzyczka N: Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 2003;77:6995-7006.
26.
Seiler MP, Miller AD, Zabner J, Halbert CL: Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum Gene Ther 2006;17:10-19.
27.
Dodiya HB, Bjorklund T, Stansell J 3rd, Mandel RJ, Kirik D, et al: Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 2010;18:579-587.
28.
Markakis EA, Vives KP, Bober J, Leichtle S, Leranth C, et al: Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther 2010;18:588-593.
29.
Hedreen JC, DeLong MR: Organization of striatopallidal, striatonigral, and nigrostriatal projections in the macaque. J Comp Neurol 1991;304:569-595.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.